INTRODUCTION

Healthcare expenditure is increasing steadily worldwide and prescription drug spending is increasing and out-of-pocket expenses are 80% of total health-care expenditures [1]. In developing countries, out-of-pocket payment is as high as 80% of healthcare spending and a similar scenario are observed in the Indian healthcare system. Between 1998 and 2004, the average real expenditure per hospital admission increased three times in both government and private hospitals. Most healthcare expenses are paid out of pocket by patients and their families, rather than through medical insurance. This has led over 35% of Indian households to incur Catastrophic Health Expenditure (CHE) and hence poses a burden of affordability of medicine [2, 3]. Generic medicine utilization is often encouraged to curb the cost of medicine as the generic product are usually lower in price than innovator brands leading to substantial savings of health care expenditure [4-6].

Although the generic medicines are bioequivalent of their innovator products and are produced according to good manufacturing practices (GMP), physicians are apprehensive regarding the quality and reliability of generic drugs as compared to their brand innovator and resist prescribing them [7, 8]. Therefore understanding doctor’s perceptions and an understanding of generic medicines may help in recognizing possible barriers to greater generic medicine usage. Hence, the primary objective of this study was focused to explore knowledge, attitude, and practice (KAP) of doctors toward generic medicines.

MATERIALS AND METHODS

Methods

The study was conducted in a tertiary-care teaching hospital in North-East India after obtaining due permission from the institutional ethics committee (NEIGR/IEC/2015/0039).
and respective answers on different categories of the questionnaires.

RESULTS

Response rate: A total of 86 questionnaires was distributed among the health care professionals and 32 responded (response rate 37%).

Demographic characteristics: The demographic details of the participants have been summarized in table 1.

Knowledge

Seventy-eight percent (78%) doctors agreed that generic medicine is bioequivalent to a brand name medicine. Seventy-two percent (72%) and seventy-five percent (75%) doctors were aware that generic medicines are the same dosage form and contain the same dose as the brand name medicines, respectively. Eighty-four (84%) doctors did not agree that generic is less effective and produce more side effects than brand name medicines. Sixty-six percent (66%) doctors disagreed that brand name drugs meet higher safety standard, but seventy-two percent (72%) doctors were not satisfied with the quality of generic drugs. Seventy-two percent (72%) doctors were unaware that generic drugs can be only marketed after the expiry date of the patent of original drugs. Among study participants, fifty (50%) doctors knew that generic drug manufacturers need not repeat the preclinical and clinical studied of original drugs but eighty-one percent (81%) doctors were aware that generic drug manufacturers need to conduct bioequivalence studies to show the equivalence of generic and original drugs.

Among the participants, fifty-six (56%) doctors told that they were aware regarding the JanAushadhi scheme and eighty-four (84%) doctors were aware of the Indian Medical Council (IMC) act to prescribe drugs with generic names.

Knowledge related questionnaires and their responses are summarized in table 2.

Table 1: Demographic details of the participants (n = 32)

| Factors          | Frequency (%) |
|------------------|---------------|
| Gender           |               |
| Male             | 66            |
| Female           | 34            |
| Age (years)      |               |
| 20–30            | 66            |
| 30–40            | 34            |
| Qualification    |               |
| MBBS             | 66            |
| MD               | 28            |
| DM               | 06            |

Table 2: Knowledge-related questions and frequency (%) of responses

| S. No. | Questions                                                                 | Yes (%) | No (%) |
|--------|---------------------------------------------------------------------------|---------|--------|
| 1      | A generic medicine is bioequivalent to a brand name medicine              | 78      | 13     |
| 2      | A generic medicine must be in the same dosage form as the brand name medicine | 72      | 28     |
| 3      | A generic medicine must contain the same dose as the brand name medicines | 75      | 22     |
| 4      | Generic medicines are less effective compared to brand name medicines     | 13      | 84     |
| 5      | Generic medicines produce more side effects compared to brand name medicines | 13      | 84     |
| 6      | Brand name medicines meet higher safety standards than generic medicines  | 31      | 66     |
| 7      | Generic drugs can be only marketed after the expiry date of the patent of original drug | 19      | 72     |
| 8      | Generic drug manufacturer need to repeat the preclinical and clinical studies required for original drug | 50      | 44     |
| 9      | Generic drug manufacturers need to conduct bioequivalence studies to demonstrate equivalence between the generic medicine and the original drug | 81      | 13     |
| 10     | Are you aware of the scheme of Government of India called Jan Aushadhi?  | 44      | 56     |
| 11     | Are you aware about the Indian Medical Council (IMC) Act to prescribe drugs with Generic names | 84      | 16     |
| 12     | Are you satisfied with the quality control measure of generic medicines by the Regulatory authority | 25      | 72     |

Attitude

Majority of doctors (69%) were of the view that generic drugs were as safe as branded drugs and eighty-four percent (84%) doctors felt that there is a huge price difference so that they prescribe cheaper generic substitutes. Seventy-five percent (75%) doctors did not agree that generic drugs cost less because they are inferior to brand name drugs and sixty-six percent (66%) doctors agreed that both generic and branded drugs have the same quality in general.

Another sixty-two percent (62%) doctors disagreed that brand names are easy to remember, eighty-seven (87%) doctors felt that both prescriber and pharmacist if work together, there is more use of generic drugs in society and ninety-four percent (94%) participants felt that there should be a standard guideline to prescribe generic medicines. Only 91% of doctors mentioned they give enough information to the patients about generic medicines and their price differences. It is observed that 72% of participants felt that they need more information related to safety and efficacy of generic medicines, and 38% of doctors felt that advertisement by the drug companies will influence their future prescribing pattern.

Majority of doctors (91%) agreed that there should be a training program to increase the awareness regarding generic drug use among doctors and patients and there should be a general medicine store in every hospital. Only 38% of doctors are satisfied with the marketing permission process granted to generic medicines and not satisfied with the quality control measures of it.

Attitude related questionnaires and their responses are summarized in table 3.

Practice

Majority of doctors (78%) prescribed generic drugs to their patients and 63% of them prescribed as much as 1 to 3 generics per prescription. Doctors prescribe generic medicine for their patients and themselves in 69% and 63% cases, respectively. As many as 47% of doctors discussed with their patients regarding generic drugs and 84% of them felt that the patient’s socioeconomic condition influenced their prescription, as shown in table 4.

Seventeen (53%) out of the total respondent of doctors did not think that switching all patients from branded drugs to generic may change the outcome of the therapy, but only 38% of participants thought switching brand name drugs with narrow therapeutic range to generic may change the outcome of the patient. Most of the doctors (38%) got information regarding the availability of generic drugs from the Internet, followed by Journal (12.5%), Drug
sten in earlier studies. A clinical study for the generic product imposed on generic drugs is better than the brand name medicine during generic product approval system. Our finding bioequivalence studies In the present study, the majority of the brand name medicine stated correct knowledge about generic medicine being medicines. It is quite similar to the earlier study by Jamshed and Hassali, the active component, dose and bioequivalent as the brand name medicine. The majority of doctors who participated in this survey perceived that generic medicine is effective, safe and needs to have the same active component, dose and bioequivalence as the brand name medicines. It is quite similar to the earlier study by Jamshed et al as stated correct knowledge about generic medicine being a "Copy of the brand name medicine" [11, 12].

In the present study, the majority of doctors (81%) were aware of bioequivalence studies, which are required by generic drug manufacturers during generic product approval system. Our finding is better than the finding reported by Chua et al. and Hassali et al. where 46% and 33.33% doctors respectively were aware of the bioequivalence standards for generic products [12, 13].

Most of the respondents in our study were unaware about some regulatory requirements (like generic marketed after the expiry of the patent of the originator or no need to repeat preclinical and clinical study for the generic product) imposed on generic drugs as stated in earlier studies [14]. A large number of doctors (72%) were of the view that generic was manufactured to the poorer quality than brand name medicines. According to the present analysis, close to three-quarters of the participants had a good attitude about the efficacy and safety of generic medicines, and the majority of doctors actively prescribe generic medicines similar to the earlier study [15, 16]. Moreover, various studies have reported that generic medicines neither differ substantially from their innovator counterparts nor related to poor efficacy or safety and even favored the use of generic drugs in treating various diseases [17, 18].

In our survey, the majority of doctors were aware of the huge price difference between generic and brand name products, and they give enough information to the patient about generic medicines with their price differences. They also prescribe cheaper generic substitutes, considering the patient socioeconomic condition. It was earlier reported that the cost of generic medicines is up to 91% less than that of the brand name drugs [19-22].

The rising health care expenses remain a serious concern for the health care system worldwide, especially in developing countries like India where availability and affordability of medicine are a major concern. To tackle this problem, the Indian Government started a project "Jan Ausadhi" to supply essential low priced generic medicine on-demand to Jan Ausadhi stores. Only half of the participants in our study were aware of regarding Jan Ausadhi Scheme. The expansion of the generic market should have a positive impact on patients’ access to cheaper drugs [22-25].

Though most of the participating doctors received a free sample of branded drugs and half of the participants were visited weekly by representatives of generic drug manufacturers never visited them but 59% of doctors were visited weekly by Representative of brand name drugs manufacturers.

Table 3: Attitude-related questions and frequency (%) of responses

| S. No. | Questions                                                                 | Disagree (%) | Neutral (%) | Agree (%) |
|--------|---------------------------------------------------------------------------|--------------|-------------|-----------|
| 1      | Generics are as safe as branded drugs                                     | 13           | 19          | 69        |
| 2      | The price difference between generic and brand name drugs is often so great that I feel I must prescribe generic substitutes | 0            | 16          | 84        |
| 3      | Generic drugs cost less because they are inferior to Brand name drugs     | 75           | 6           | 16        |
| 4      | Generic medicines are generally of the same quality as brand-name drugs   | 19           | 16          | 66        |
| 5      | It is easier to remember brand names, rather than generic drug names       | 62           | 16          | 22        |
| 6      | Quality use of generic medicines among patients can be achieved if both prescribers and pharmacist work together | 0            | 13          | 87        |
| 7      | We need a standard guideline to prescribe generic medicines                | 0            | 6           | 94        |
| 8      | Patient should be given enough information about generic medicines in order to make sure they really understand about the medicines they take | 0            | 9           | 91        |
| 9      | Advertisement by the drug companies will influence my future prescribing pattern | 22           | 38          | 38        |
| 10     | Need more information on the issues pertaining to the safety and efficacy of generics | 0            | 25          | 72        |
| 11     | There should be a training program to increase awareness regarding generic drugs among doctors and patients | 0            | 9           | 91        |
| 12     | There should be a generic medicine store in every hospital                | 0            | 9           | 91        |
| 13     | Satisfied with the marketing permission process granted to generic medicine  | 34           | 28          | 38        |
| 14     | Satisfied with the quality control measures of generic medicines          | 38           | 28          | 31        |

Table 4: Practice-related questions and frequency (%) of responses

| S. No. | Questions                                                                 | Yes (%) | No (%) |
|--------|---------------------------------------------------------------------------|---------|--------|
| 1      | Do you prescribe generic drugs to your patients?                         | 78      | 19     |
| 2      | Have you ever taken Generic Medicine?                                    | 63      | 34     |
| 3      | Have you ever prescribed generic medicine to your family members?        | 69      | 28     |
| 4      | Have you ever talked to your patient regarding Generic drugs?            | 47      | 50     |
| 5      | Do you think that switching all patients from a brand name to generics may change the outcome of the therapy? | 41      | 53     |
| 6      | Do you think switching brand name drugs with narrow therapeutic range to generic may change the outcome of the therapy of patient? | 38      | 56     |
| 7      | Does the socioeconomic condition of your patient influence your prescription? | 84      | 09     |
| 8      | Have you ever received free samples of Generic drugs?                    | 16      | 81     |
| 9      | Have you ever received free samples of Brand name drugs?                 | 81      | 16     |
the representative of brand name medicine manufacturers in our study, but a few of doctors (30%) felt that advertisement by the drug company will influence their future prescribing pattern which is contradictory to earlier studies where they stated the presence of heavy and successful promotional activities from branded product industry may negatively influence generic prescribing [26-28].

More than three-quarters of doctors (78%) prescribed generic drugs and they (84%) were aware of the Indian Medical Council (IMC) Act to prescribe drugs in generic names in the present study. Our result is far better than the previous studies in Bahmin (10.2%), Belgium (2.8%), Malaysia (12.7%) and USA (2-22%) but is quite similar to the earlier studies in the UK (83%) and Thailand (73.9%) [29, 30]. This may be due to the introduction and encouraging generic prescribing at the early stage of medical school and the Indian Medical Council (IMC) Act to prescribe drugs in generic names. Even in Europe, several measures and interventions have been taken to enhance prescribing in generic medicines [30-32].

Although majority of the doctors surveyed had good knowledge and attitude about generic medicines and a meaningful proportion of doctors actively prescribed generic drugs, still more information about generic drugs are needed by them especially on quality to increase generic medicine prescription rates [33, 34]. Participating doctors also agreed that it was important to establish a greater collaboration between them and the pharmacists, in order to improve generic utilization among consumers. They also expressed the need for standard guidelines on generic substitution policy.

LIMITATION
A possible limitation of this study could be the small sample size, thus findings of this study can hardly be generalized. A further potential limitation may be the manner of participant selection as all doctors participating had a university affiliation and working in the tertiary medical teaching hospital. Other limitation may be such as the age of the participants as most of our participants are young fresh medical graduates (age range 20-40yrs and 2/3 doctors have less than 10 y of experience after their medical graduation). Lastly, we have only analyzed the doctor’s view, perception, knowledge, attitude, and practice about generic medicine prescribing. It would be appropriate also to know the attitude about generic medicines and a meaningful proportion of the need for standard guidelines on generic substitution policy.

CONCLUSION
Although majority of the doctors surveyed had good knowledge and attitude about generic medicines and a meaningful proportion of doctors actively prescribed generic drugs, still more information about generic drugs are needed by them especially on quality to increase generic medicine prescription rates. In order to have a better understanding of generic, the doctor must be well informed about the generic during their academic career resulting in savings to healthcare budgets. They also expressed the need for standard guidelines on generic substitution policy.

FUNDING
Nil

AUTHORS CONTRIBUTIONS
Dr. Chayna Sarkar, Dr. Biswadeep Das, Dr. Joonmoni Lahon, Dr. Julie Wahlang, DrBanylla shisha Nongkynrih: Design and executed the study.
Dr. Joonmoni Lahon, DrBanylla shisha Nongkynrih, Dr. DK Brahma: Validated the questionnaire and Data Analysis
Dr. Chayna Sarkar, Dr. Biswadeep Das, Dr. Julie Wahlang: Manuscript preparation

CONFLICTS OF INTERESTS
Declared none

REFERENCES
1. Dunne SS, Dunne CP. What do people really think of generic medicines? A systematic review and critical appraisal of the literature on stakeholder perceptions of generic drugs. BMC Med 2015;13:173.
2. Kumar AS, Chen LG, Choudhury M, Ganju S, Mahajan V, Sinha A, et al. Financing health care for all: challenges and opportunities. Lancet 2011;377:668-79.
3. Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997–2000. Ann Intern Med 2005;142:891-7.
4. Shaik, Muragundi. Evaluation of price disparity among generic medicines in India. Asian J Pharm Clin Res 2018;11:1:466-8.
5. Hansen Natil, Henny Lucinda, Yanwirastri Yanwirastri, Yufri Aldi, Yori Yuliani. Pharmacodynamics effect of methylprednisolone tablets on the serum concentration of annexin a1: in vivo comparative study between generic and innovator drug. Asian J Pharm Clin Res 2019;12:414-7.
6. Chong CP, Bahari R. Generic substitution in community pharmacies of penang area. Malays J Pharm Sci 2005;3:74.
7. Al rasheed, A.S., Hassali MA, Aljadhey H, Ibrahim MI, Al-Tamimi SK. Is there a need for a formulary of clinically interchangeable medicines to guide generic substitution in Saudi Arabia? J Young Pharm 2013;5:73-5.
8. Singal GL, Nanda A, Kowtani A. A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India. Indian J Pharmacol 2011;43:131.
9. Shrank WH, Liberman JN, Fischer MA, Giridish C, Brennan TA, Choudhry NK. Pharmacists perceptions about generic drugs. Ann Pharmacother 2011;45:31-8.
10. Kumar R, Hassali MA, Saleem F, Al rasheed, AA, Kaur N, Wong ZY, et al. Knowledge and perceptions of physicians from private medical centres towards generic medicines: a nationwide survey from Malaysia. J Pharm Policy Pract 2011;4:8:11.
11. Jamshed SQ, Ibrahim MI, Hassali MA, Masood I, Low BY, Shafie AA. Perception and attitude of general practitioners regarding generic medicines in Karachi, Pakistan: a questionnaire based study. South Med Rev 2012;5:22.
12. Chua GN, Hassali MA, Shafie AA, Awaisu A. A survey exploring knowledge and perceptions of general practitioners towards the use of generic medicines in the northern state of Malaysia. Health Policy 2010;95:229-35.
13. Hassle MA, Shafie AA, Awaisu A, Ibrahim MI, Ping CC, Jamshed S. Physicians’ views on generic medicines a narrative review. J Generic Med 2010;7:330-9.
14. Dunne SS, Shannon B, Cullen W, Dunne CP. Beliefs, perceptions and behaviours of GPs towards generic medicines. Fam Pract 2014;31:467-74.
15. Davit BM, Nwokah PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, et al. Comparing generic and innovator drugs: a review of 12 y of bioequivalence data from the United States food and drug administration. Ann Pharmacother 2009;43:1588-97.
16. Amit G, Rosen A, Vaghaiya M, Bonneh DY, Liss T, Grosbard A, et al. Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation. Am J Cardiol 2004;93:1558-60.
17. Arazsikiewicz AA, Szabert K, Godman B, Warszynski M, Barbu C, Haycox A. Generic dicaptopirim: health authority opportunity or nightmare?. Expert Rev Pharm Out 2008;8:549-55.
18. Kesselheim AS, Misono AS, Lee JL, Steadman MR, Brookhart MA, Choudhry NK, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA J Am Med Assoc 2008;300:2514-26.
19. Kesselheim AS, Steadman MR, Rubhrick EJ, Gagge JJ, Misono AS, Lee JL, et al Seizure outcomes following the use of generic versus brand-name antiepileptic drugs. Drugs 2010;70:605-21.
20. Lopes GD. Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India. Ann Oncol 2013;24:13-6.
21. Jayaraman K. Troubles beset ‘Jan Aushadhi’ plan to broaden access to generics. 2010;16:350.
22. Prasad. Knowledge, attitude, and practice of generic drugs among doctors in a tertiary care hospital. Innovare J Med Science 2019;7:1-3.
23. Tsiantou V, Zavras D, Kousoulakou H, Geitona M, Kyriopoulos J. Generic medicines: greek physicians’ perceptions and prescribing practices. J Clin Pharm Ther 2009;34:47-54.

24. Dejong C, Aguilar T, Tseng CW, Lin GA, Boscardin WJ, Dudley RA. Pharmaceutical industry-sponsored meals and physician prescribing patterns for medicare beneficiaries. JAMA Intern Med 2016;176:1114-22.

25. Mahajan R, Singh NR, Singh J, Dixit A, Jain A, Gupta A. Current scenario of attitude and knowledge of physicians about rational prescription: a novel cross-sectional study. J Pharm Bioallied Sci 2010;2:132-6.

26. Dyli P, Vulto A, Simoens S. Where a cheap medicine is not the same as a generic medicine: the Belgian case. J Pharm Health Serv Res 2011;2:185-9.

27. Suh DC. Trends of generic substitution in community pharmacies. Pharm World Sci 1999;21:260-5.

28. Steinman MA, Chren MM, Landefeld CS. What’s in a name? Use of brand versus generic drug names in United States outpatient practice. J Gen Intern Med 2007;22:645-8.

29. Kwo EC, Kamat P, Steinman MA. Physician use of brand versus generic drug names in 1993–1994 and 2003-2004. Ann Pharmacother 2009;43:459-68.

30. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Front Pharmacol 2011;1:141.

31. Godman B, Wettermark B, Bishop I, Burkhardt T, Fürst J, Garuoliene K, et al. European payer initiatives to reduce prescribing costs through use of generics. Gali J 2012;1:22-7.

32. Vončina L, Strizrep T, Godman B, Bennie M, Bishop I, Campbell S, et al. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev Pharm Out 2011;11:469-79.

33. Fabiano V, Mameli C, Cattaneo D, Delle Fave A, Preziosa A, Mele G, et al. Perceptions and patterns of use of generic drugs among Italian family pediatricians: first-round results of a web survey. Health Policy 2012;104:247-52.

34. Pandianunni, Kartik J Salwe, Somasundaram G, Bhanu Prakash Kolasani. A study on the prescribing pattern of antimicrobial agents in the neonatal intensive care unit of a tertiary care teaching hospital in puducherry, South India. Asian J Pharm Clin Res 2016;9:217-20.